Bioequivalence Study Optimization
Design FDA/EMA-compliant bioequivalence study protocols with optimized sample sizes
What You Can Do
This skill helps you design scientifically rigorous and regulatory-compliant bioequivalence study protocols in a fraction of the time. Claude analyzes FDA and ICH guidance documents to extract all applicable requirements, calculates statistically powered sample sizes for your specific formulation and study design, and generates protocol drafts structured for regulatory review. You'll identify compliance gaps, risk mitigate protocol weaknesses, and accelerate CRO handoff with submission-ready documentation.
Features
Systematically extract and cross-reference FDA/ICH BE requirements specific to your formulation type (immediate-release, extended-release, modified-release)
Generate scientifically sound protocol drafts pre-aligned to regulatory expectations with all required sections and justifications
Calculate sample sizes, evaluate crossover design options, and justify statistical assumptions based on pharmacokinetic parameters
Evaluate biowaiver eligibility versus full BE study need based on solubility, permeability, and dissolution data
Detect protocol gaps, missing justifications, and compliance issues before CRO submission to reduce iteration cycles
Cross-reference similar approved BE studies and products to anticipate reviewer questions and strengthen defensibility
Structure age, renal/hepatic impairment, food effect, and DDI study rationale aligned to guidance
Generate chemistry/manufacturing controls references and bioanalytical method validation links for integrated regulatory packages
Example Output
Example 1: Extended-Release Formulation Protocol Outline
Study Design Section Generated:
- Randomized, two-way crossover, single-dose design
- Sample size: n=32 (calculated for 90% power, CV=28% based on literature, BE limits 80-125%)
- Washout period: 14 days (≥5 half-lives per FDA guidance for this BCS II compound)
- Food effect: Fed state per FDA Extended-Release guidance
- Justification: Previous fed/fasted crossover data supports fed as worst case
Example 2: Biowaiver Decision Support
Claude analyzes your dissolution, BCS classification, and P-gp substrate data to recommend: "Full BE study required. While your compound meets BCS Class II criteria (low solubility, high permeability), dissolution shows pH-dependent profiles across GI pH range. FDA precedent for similar ER products (cites 2 reference products) requires in vivo BE despite biowaiver-eligible BCS classification."
Example 3: Statistical Power Calculation Output
For your proposed n=24 crossover design:
- Power = 87% (below 90% target)
- Recommendation: Increase to n=28 to achieve 91% power
- Sensitivity analysis provided: accounts for anticipated CV=26-30% range based on intra-subject variability literature
What's Included
- SKILL.md instruction file: Complete skill setup and usage context
- BE Protocol Template: Structured sections (objectives, endpoints, study design, statistical analysis plan, safety monitoring)
- Sample Size Calculator Worksheet: Pre-formatted spreadsheet with FDA BE parameters and crossover design options
- FDA/EMA Guidance Checklist: Mapped compliance requirements by formulation type (IR, ER, MR, special populations)
- Biowaiver Decision Framework: BCS classification assessment tool and regulatory pathway selection logic
- Risk Assessment Template: Protocol gap identification checklist and compliance validation matrix
Who It's For
- Bioequivalence Study Managers — Designing protocols and managing CRO timelines
- Bioanalytical Scientists — Structuring method validation strategies within BE study designs
- Regulatory Affairs Specialists — Anticipating FDA/EMA questions and ensuring submission readiness
- Formulation Scientists — Evaluating BE pathway decisions (biowaiver vs. full study) for new products
- Clinical Research Organization Partners — Preparing protocol briefing documents and compliance assessments
Best For
- New NDA/ANDA bioequivalence protocol development
- Complex formulation BE designs (extended-release, modified-release, special populations)
- Biowaiver feasibility assessment and regulatory pathway selection
- Sample size justification and statistical power optimization
- FDA/EMA guidance compliance gap analysis and risk mitigation
You might also like
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
by kody-wClaude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
Conduct comprehensive job risk assessments in minutes, generate detailed task analysis reports with biomechanical findings, and develop prioritized ergonomic interventions backed by OSHA and NIOSH guidelines. You'll identify risk factors, quantify hazard severity, and produce actionable recommendations that reduce worker injury rates and improve compliance documentation.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
Analyze your power system topology, coordinate protective devices for optimal selectivity and speed, and generate comprehensive arc flash hazard analyses compliant with IEEE 1584. You get fault current calculations, device coordination plots, and hazard risk assessments that guide equipment upgrades and safety training.
by kody-w
You can rapidly diagnose why your solid dose formulations are failing—whether due to poor flowability, insufficient hardness, moisture sensitivity, dissolution issues, or API degradation. The skill walks you through structured root-cause analysis, maps chemical interactions between your drug substance and excipients across pH, temperature, and moisture conditions, then prioritizes excipient replacements based on regulatory precedent and manufacturing feasibility. You'll document all decisions with clear rationale ready for CMC submissions.
by kody-w
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w